Recent Articles in Industry Insights

In 2021, China set impressively higher records in Life Science investing, despite the COVID-19 pandemic. Most categories followed by ChinaBio® hit new all-time highs, signaling high levels of investments in several areas important to China life science companies. According to Greg Scott, Founder and CEO of ChinaBio®, the total value of China life science transactions climbed 55% from 2020's levels, a significant advance under any circumstances, but especially strong given the restrictions of COVID. He delivered the 2021 Report on China Life Science Investment as the Keynote Address at the virtual China Showcase, part of Biotech Showcase™. More details....

Share this with colleagues:

Deals and Financings 

• France's Sanofi will acquire Kadmon, a New York city pharma with a China JV and a newly approved graft-versus-host drug, in a $1.9 billion deal;
• Frontage Shanghai, a division of US-China CRO Frontage Holdings, acquired a 70% stake in Wuhan Heyan Biomedical Technology, a discovery CRO;
• Bio-Thera Solutions out-licensed US, EU and Canadian commercial rights for its Avastin biosimilar to Sandoz;
• Huadong Medicine entered a partnership with Insilico Medicine, a Hong Kong AI drug discovery company, to develop small-molecule oncology candidates; 

Covid-19 Pandemic 

• Brii Biosciences of Beijing committed an additional $100 million for global regulatory filings and commercialization of its SARS-CoV-2 combination therapy;
• Chengdu Clover Biopharma received a permit to manufacture its S-Trimer COVID-19 vaccine candidate at its Changxing facility;
• Sinovac Biotech said a third dose of its SARS-CoV-2 vaccine improved the protection of CoronaVac® by 60%, including protection from the Delta variant; 

Trials and Approvals 

• JW Therapeutics, a Shanghai CAR-T company, was approved to launch its anti-CD-19 CAR-T to treat large B-cell lymphoma in China. 

Stock Symbols: (NSDQ: KDMN) (SHA: 688177) (SHZ: 000963) (NSDQ: SVA) (HK: 2126)

In late May, Shanghai's municipal government announced a set of cash incentives for Shanghai companies that are developing new drugs, medical devices or signing contract manufacturing agreements. Shanghai will underwrite 40% of a novel drug's R&D expenses if the drug qualifies for China 1.1 status (candidates never approved anywhere). In addition, other new biologics will receive up to $1.5 million and chemical drugs $500,000, while new TCM therapies will be eligible for up to $4.5 million. The plan was originally described by Brian Yang of Pink Sheet (see article), who generously allowed ChinaBio™ Today to use the information. More details....

Share this with colleagues: